【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Antithrombotic Drugs
1.2 Why Should You Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
1.10 Glossary of Abbreviations
2. Blood Clotting: Mechanisms, Disorders and Current Treatments
2.1 Understanding Haemostasis and Coagulation
2.2 What is Thrombosis
2.3 Complications of Thrombosis
2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
2.4 Antithrombotic Drug Treatment
3. Antithrombotic Drugs: World Market 2015-2025
3.1 The World Antithrombotic Drug Market in 2013 and 2014
3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2014-2025
3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
3.3.1 An Increasing Patient Population Drives Market Growth
3.3.2 Intense Competition from Generics Threatens to Restrain the Market
3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025
3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
3.6 Anticoagulant Drugs: Leading the Market from 2014 Onwards
3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential
3.6.2 Heparins: Second-Leading Anticoagulant Class in 2013
3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2013 and 2014
3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2014
3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market
4. Leading Products in the Market: Prospects, 2015-2025
4.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic Competition
4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2019 and 2025
4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2025?
4.4 Plavix Faces Competition from Generics, So What Does the Future Hold?
4.4.1 Branded Competition for Plavix?
4.5 Lovenox: Biosimilar Competition in the EU is Expected
4.6 Xarelto: Leading Antithrombotic of 2014
4.7 Pradaxa’s Continued Growth in 2014
4.8 Activase Leads the Fibrinolytics Market, With Little Competition
4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix
4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US
4.14 Sandoz’s Enoxaparin Sodium: Revenue Forecast 2014-2025
4.15 Fragmin Faces Rivalry from Generic Competition to Lovenox
4.16 Brilinta/Brilique: Investigation Closed in 2014
4.17 Eliquis: Will Late Entry to the Market Affect Uptake?
4.18 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK
4.19 New Approvals in the Antithrombotic Drugs Market, 2014
4.19.1 Zontivity: The Newest Approval in Antithrombotics
4.19.2 Lixiana/Savaysa: Expansion into Other Regional Markets
5. Leading National Markets, 2014-2025
5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2013 and 2014?
5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2019 and 2025
5.3 Which National Markets Will Grow Fastest to 2025?
5.4 The US: Dominating the Antithrombotic Drug Market Through 2014-2025
5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
5.5.1 Germany Leads the EU5
5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
5.5.3 UK: Pharmaceutical Price Regulation Scheme
5.5.4 Italy’s Healthcare System – Advantages Conducive to Business
5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth
5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2015-2025
5.7 Chinese Antithrombotic Drug Market Will Capture Market Share
5.8 Brazilian Antithrombotic Drug Market 2015-2025: Strong Growth as Universal Healthcare Coverage is Expanded
5.9 Indian Antithrombotic Drug Market – Limited by Governmental Healthcare Spending?
5.10 Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth
6. Antithrombotic Drug Development: R&D Pipeline
6.1 The R&D Pipeline for Antithrombotic Drugs: Overview
6.2 The Antiplatelet Drug R&D Pipeline in 2014
6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
6.2.2 The Medicines Company’s Kangrexel (Cangrelor) Awaits Approval
6.3 The R&D Pipeline for Anticoagulants, 2014
6.3.1 Heparins: Little R&D Activity in 2014
6.3.1.1 Will Development of Momenta’s Adomiparin Continue?
6.3.1.2 The Discontinuation of Semuloparin
6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014
6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
6.3.5 Portola Pharmaceuticals’ Betrixaban
6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban
6.4 The Fibrinolytics R&D Pipeline, 2014
6.4.1 Lundbeck’s Desmoteplase: Failed to Meet Primary Endpoint in Phase III
6.4.2 Bharat Biotech and ThromboGenics’ THR-100
6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2014
6.5.1 Kyowa Hakko Kirin’s KW-3357: Filed in Japan, 2014
6.5.2 Asahi Kasei Pharma America’s ART 123
6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote
6.5.4 Isis Pharmaceuticals’ ISIS-FXI Rx
7. Leading Companies in the Antithrombotic Drug Market
7.1 Leading Antithrombotic Drug Manufacturers in 2014
7.2 Sanofi Leads the Market, but is its Position Under Threat?
7.3 Boehringer Ingelheim Captures Market Share
7.4 Bayer Markets Two Antithrombotic Drugs
7.5 Johnson & Johnson Can Achieve Success with a Limited Product Portfolio
7.6 Genentech Will Retain Market Share
7.7 The Medicines Company’s Position Will be Bolstered by the Launch of its New Drug
7.8 Eli Lilly: Market Position is Dependent on Success of Effient
7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
7.10 Pfizer: A Gradually Increasing Share of the Market
7.11 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013
8. Qualitative Analysis of the Antithrombotic Drugs Market, 2015
8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2015
8.1.1 Thrombotic Disease: Management Rather Than Cure
8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
8.2 Opportunities and Threats Facing the Market 2015-2025
8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
8.2.2 Further Development of Existing Drugs
8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
8.2.4 The Threat of Generic Competition
8.2.5 High Level of Competition is a Threat to New Entrants – What Can Developers Do?
8.2.6 High Risk of Investment in New Drug Development
8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2015-2025
8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
8.3.3 Economic Factors
8.3.3.1 Cost Cutting in the EU and the US
8.3.3.2 Free Trade within the EU Presents Challenges
8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?
9. Research Interviews
9.1 Interview with Dr Sanjay Bhanot, PhD, Vice President of Clinical Development and Translational Medicine, Isis Pharmaceuticals, Inc.
9.1.1 Isis Pharmaceuticals Antithrombotic Drugs Pipeline
9.1.2 ISIS-FXIRx Phase II Results
9.1.3 Trends in the Antithrombotic Drug Market, 2015-2025
9.2 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology, Department of Biochemistry, Universidade Federal de São Paulo, Brazil
9.2.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp
9.2.2 Heparin vs. Novel Oral Anticoagulants
9.2.3 Unmet Needs in Brazil and Worldwide
9.2.4 Trends in the Antithrombotic Drug Market
10. Conclusions from Our Study
10.1 The World Market for Antithrombotic Drugs 2015-2025
10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
10.2 The Leading National Markets 2015-2025
10.3 Trends in the Industry
10.3.1 The Market Will Recover From Plavix Decline
10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
10.3.4 High Barriers to Market Entry and a Limited Pipeline – The Implications
【レポート販売概要】
■ タイトル：抗血栓薬の世界市場：抗凝固薬、抗血小板薬■ 英文：Antithrombotic Drugs: World Industry and Market Prospects 2015-2025
■ 発行日：2015年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN5040808
■ 調査対象地域：グローバル
- 世界の潜水艦市場動向2013-2023：市場のSWOT分析This SWOT analysis of Submarine market is a crucial resource for industry executives and anyone looking to gain a better understanding of the market. SDI's "The Global Submarine Market 2013-2023 - SWOT Analysis: Market Profile" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. SDI strictly follows a standar …
- 健康サプリメントの世界市場2016-2026The latest report from business intelligence provider visiongain offers comprehensive analysis of the global wellness supplements market. Visiongain assesses that this market will generate revenues of $236.93bn in 2016. Now: “Are Your Vitamins And Supplements Safe and Right For You?” This is an example of the business critical headline that you need to know about - and more importantly, you need t …
- エアロスタット（軽航空機）の世界市場2016-2020About Aerostat SystemsAn aerostat uses gases lighter than air such as hydrogen, helium, as well as hot air, which helps the aerostat to generate airlift. Aerostats include powered airships and unpowered balloons that are tethered to the ground. These are generally used for intelligence, surveillance, and reconnaissance (ISR) purposes by the military forces and for tourism and civilian observations …
- 安全スイッチの世界市場2016-2020About the Safety Switches Market The demand for safety switches has increased considerably at present compared to the last decade. This is evident from the growing applications of automated systems and industrial robots in manufacturing and industrial production, besides the increasing urban population and the subsequent electricity consumption patterns. The increase in robotic applications in ind …
- 胎児・新生児ケア装置の世界市場2016-2020About Premature Infants Premature infants are born due to many factors such as induced fertility, poor prenatal care, labor treatments, advanced maternal age, and changing lifestyles such as drinking and smoking. At birth, various disorders are diagnosed such as hyperbilirubinemia, bronchopulmonary dysplasia, intraventricular hemorrhage, transient tachypnea, and anemia. Therefore, proper prenatal …
- 末梢血管診断装置の世界市場2016-2020：糖尿病、 重症虚血肢About Peripheral Vascular Diagnostic SystemsThe global peripheral vascular diagnostic systems market is expected to grow at a steady pace during the forecast period. The market has a vast opportunity in both developed and untapped developing countries. To increase their market share, vendors are focusing on providing novel technologies that decrease the follow-up visits to physicians' clinics and …
- 持続的標的型攻撃（APT）対策ソリューションの世界市場Advanced persistent threat protection market is concerned with the prevention, detection, and mitigation of sophisticated threats such as zero-day vulnerabililties and other advanced threats. These advanced threats can easilty evade traditional network security leaving enterprise networks at huge risks to the theft of valuable intellectual properties. Hence, enterprises are rapidly adopting the mu …
- 関節リウマチ治療薬の世界市場：DMARD、NSAID、コルチコステロイド、鎮痛薬About Rheumatoid Arthritis Drugs RA is a chronic inflammatory autoimmune disease seen in people aged between 30 and 60 years. The symptoms of the disease appear slowly, with mild pain around the joints coupled with stiffness and fatigue. In the later stages, it causes inflammation of the joints. Genetic and environmental elements are known to contribute to the development of the condition. DMARDs, …
- 世界の肺炎検査市場The report presents a detailed analysis of the Pneumonia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Pneumonia definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Comm …
- 2014年戦略提言：イギリスの呼吸器病診断検査市場About This ReportThis new 281-page report from Venture Planning Group presents detailed analysis of the UK Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals, Commercial and Public Health Labs.In additio …
- OSDF (経口固形製剤) 用溶解性強化賦形剤の世界市場About solubility enhancement excipients for OSDF Excipients are inactive components of a drug that are used in conjunction with API. Though they are often referred to being inert, excipients play important functional roles in drug delivery. Some of the key functions include binding, flavoring, coloring, lubricating, and enhancing solubility of the drug. Solubility enhancing excipients are relative …
- Siemens Healthcare：市場シェア分析Siemens Healthcare Market Share Analysis Summary GlobalData’s new report, “Siemens Healthcare Market Share Analysis” provides in-depth information on Siemens Healthcare’s market position in the different medical equipment markets it operates in. The report provides Siemens Healthcare market share information in eighteen key market categories – Hearing Aid Devices, Clinical Chemistry, Genetic Testi …
- 高性能接着剤の世界市場予測（～2022年）：エポキシ、ポリウレタン、アクリル、シリコーンThe increasing demand for high-performance adhesives across various end-use industries is driving the global high-performance adhesives market. In terms of value, the global market size is estimated at USD 9.77 Billion in 2017 and is projected to reach USD 13.17 Billion by 2022, at a CAGR of 6.15% between 2017 and 2022. Asia-Pacific accounts for a major share of the overall high-performance adhesi …
- 世界のトップ10 SDx・ネットワーク技術市場“The increasing need for simplified network architecture and enhanced security is expected to drive the growth of the software-defined everything and networking technologies”The top 10 Software-Defined Everything (SDx) and networking technologies market is expected to grow at a significant rate between 2016 and 2021. This report covers the major SDx and networking technologies, such as Software-De …
- ブロックチェーン技術の世界市場分析：、タイプ別（公共、私用、混合）、用途別（金融サービス、消費者/工業製品、テクノロジー、メディア･テレコム、ヘルスケア、交通、公共部門）、地域別、セグメント予測、2015 – 2024The global blockchain technology market is expected to reach USD 7.74 billion by 2024, according to a new report by Grand View Research, Inc. Blockchain is the underlying technology that originated in the form of a public ledger to keep a track of all cryptocurrency transactions. The technology works as an electronic transaction-processing and record-keeping system. This allows various participant …
